TY - UNPB
T1 - Business Model Innovation in the Pharmaceutical Industry
T2 - The Supporting Role of Organizational Design
AU - Ahrensbach Rasmussen, Klement
AU - Foss, Nicolai J.
PY - 2014/2
Y1 - 2014/2
N2 - Based on interviews in LEO Pharma, UCB Pharma and Novo Nordisk, we document how deep-seated changes in the pharmaceutical industry related to increasing demands from payers, the strengthening of the role of patients, changing legal demands, and declining technological opportunity, drive a process of experimenting with business model. We distinguish between three ideal types, namely a traditionalist model (exemplified by Novo Nordisk), the full-blown service-oriented model (UCB Pharma) and the in-between model (LEO Pharma). We describe the changes to the organizational design and management processes that accompany the ongoing process of changing business models in these firms.
AB - Based on interviews in LEO Pharma, UCB Pharma and Novo Nordisk, we document how deep-seated changes in the pharmaceutical industry related to increasing demands from payers, the strengthening of the role of patients, changing legal demands, and declining technological opportunity, drive a process of experimenting with business model. We distinguish between three ideal types, namely a traditionalist model (exemplified by Novo Nordisk), the full-blown service-oriented model (UCB Pharma) and the in-between model (LEO Pharma). We describe the changes to the organizational design and management processes that accompany the ongoing process of changing business models in these firms.
KW - The pharmaceutical industry
KW - Business model innovation
KW - Organizational design
KW - The pharmaceutical industry
KW - Business model innovation
KW - Organizational design
M3 - Working paper
SN - 9788791815966
T3 - SMG Working Paper
BT - Business Model Innovation in the Pharmaceutical Industry
PB - Institut for Strategic Management and Globalization
CY - Frederiksberg
ER -